The Clinical Benefits of Antiretroviral Therapy in Severely Immunocompromised HIV-1-Infected Patients with and without Complete Viral Suppression

Abstract

Background

The aim of this study was to determine whether there is a protective effect of combination anti-retroviral therapy (cART) on the development of clinical events in patients with ongoing severe immunosuppression.

Methods

A total of 3,780 patients from the EuroSIDA study under follow-up after 2001 with a current CD4⁺ T-cell count ≤200 cells/mm³ were stratified into five groups: group 1, viral load (VL)<50 copies/ml on cART; group 2, VL 50-99,999 copies/ml on cART; group 3, VL 50-99,999 copies/ml off cART; group 4, VL≥100,000 copies/ml on cART; and group 5, VL≥100,000 copies/ml off cART. Poisson regression was used to identify the risk of (non-fatal or fatal) AIDS- and non-AIDS-related events considered together (AIDS/non-AIDS) or separately as AIDS or non-AIDS events within each group.

Results

There were 428 AIDS/non-AIDS events during 3,780 person-years of follow-up. Compared with group 1, those in group 2 had a similar incidence of AIDS/ non-AIDS events (incidence rate ratio [IRR] 1.04; 95% CI 0.79–1.36). Groups 3, 4 and 5 had significantly higher incidence rates of AIDS/non-AIDS events compared with group 1; incidence rates increased from group 3 (IRR 1.78; 95% CI 1.25–2.55) to group 5 (IRR 2.36; 95% CI 1.66–3.40), demonstrating the increased incidence of AIDS/non-AIDS events associated with increasing viraemia. After adjustment, the use of cART was associated with a 40% reduction in the incidence of AIDS/non-AIDS events in patients with VL 50–99,999 copies/ml (IRR 0.59; 95% CI 0.41–0.85) and in those with a VL>100,000 copies/ml (IRR 0.66; 95% CI 0.44–1.00). Similar relationships were seen for non-AIDS events and AIDS events when considered separately.

Conclusions

In patients with ongoing severe immuno-suppression, cART was associated with significant clinical benefits in patients with suboptimal virological control or virological failure.

References

Mocroft

, Ledergerber

, Katlama

Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22–29.

Murphy

E.L.

, Collier

A.C.

, Kalish

L.A.

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17–26.

Palella

F.J.

Jr. , Delaney

K.M.

, Moorman

A.C.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–860.

Vittinghoff

, Scheer

, O'Malley

, Colfax

, Holmberg

S.D.

, Buchbinder

S.P.

Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179: 717–720.

MacArthur

R.D.

, Perez

, Walmsley

, Baxter

J.D.

, Mullin

C.M.

, Neaton

J.D.

Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials 2005; 6: 127–135.

Miller

, Phillips

A.N.

, Clotet

Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186: 189–197.

Sterling

T.R.

, Chaisson

R.E.

, Moore

R.D.

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15: 2251–2257.

Yerly

, Perneger

T.V.

, Hirschel

A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. Arch Intern Med 1998; 158: 247–252.

Kozal

M.J.

Drug-resistant human immunodefiency virus. Clin Microbiol Infect 2009; 15 Suppl 1: 69–73.

10.

Daar

E.S.

, Richman

D.D.

Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses 2005; 21: 343–357.

11.

Aleman

, Soderbarg

, Visco-Comandini

, Sitbon

, Sonnerborg

Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002; 16: 1039–1044.

12.

Deeks

S.G.

Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. JAMA 2001; 286: 224–226.

13.

Lampe

F.C.

, Smith

C.J.

, Madge

Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167: 692–700.

14.

Sabin

C.A.

, Phillips

A.N.

, Yee

T.T.

, Griffoen

, Lee

C.A.

Twenty five years of HIV infection in haemophilic men in Britain: an observational study. BMJ 2005; 331: 997–998.

15.

Achhra

A.C.

, Amin

, Law

M.G.

Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010; 24: 1877–1886.

16.

Mocroft

, Reiss

, Gasiorowski

Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55: 262–270.

17.

Mocroft

, Katlama

, Johnson

A.M.

AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356: 291–296.

18.

Miller

, Mocroft

, Reiss

Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999; 130: 570–577.

19.

US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. AIDSinfo. (Updated 27 March 2012. Accessed 13 August 2012.) Available from http://AIDSinfo.nih.gov.

20.

Thompson

M.A.

, Aberg

J.A.

, Cahn

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321–333.

21.

Mellors

J.W.

, Rinaldo

C.R.

Jr. , Gupta

, White

R.M.

, Todd

J.A.

, Kingsley

L.A.

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167–1170.

22.

Mellors

J.W.

, Munoz

, Giorgi

J.V.

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946–954.

23.

Lifson

A.R.

, Belloso

W.H.

, Davey

R.T.

Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials 2010; 11: 205–219.

24.

Marin

, Thiebaut

, Bucher

H.C.

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23: 1743–1753.

25.

Neuhaus

, Angus

, Kowalska

J.D.

Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24: 697–706.

26.

Mocroft

, Vella

, Benfield

T.L.

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725–1730.

27.

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1–19.

28.

Kowalska

J.D.

, Mocroft

, Ledergerber

A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clin Trials 2011; 12: 109–117.

29.

Kowalska

J.D.

, Friis-Moller

, Kirk

The Coding Causes of Death in HIV (CoDe) Project: Initial Results and Evaluation of Methodology. Epidemiology 2011; 22: 516–523.

30.

El-Sadr

W.M.

, Lundgren

J.D.

, Neaton

J.D.

CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283–2296.

31.

Guiguet

, Porter

, Phillips

, Costagliola

, Babiker

Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART). Open AIDS J 2008; 2: 3–9.

32.

Sterne

J.A.

, Hernan

M.A.

, Ledergerber

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378–384.

33.

Torti

, Lapadula

, Maggiolo

Predictors of AIDS-defining events among advanced naive patients after HAART. HIV Clin Trials 2007; 8: 112–120.

34.

Moore

R.D.

, Gebo

K.A.

, Lucas

G.M.

, Keruly

J.C.

Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 2008; 47: 1102–1104.

35.

Phillips

A.N.

, Carr

, Neuhaus

Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177–187.

36.

Deeks

S.G.

HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62: 141–155.

37.

Hogg

, Lima

, Sterne

J.A.

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293–299.

38.

Bhaskaran

, Hamouda

, Sannes

Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300: 51–59.

39.

Effros

R.B.

, Dagarag

, Spaulding

, Man

The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev 2005; 205: 147–157.

40.

Appay

, Almeida

J.R.

, Sauce

, Autran

, Papagno

Accelerated immune senescence and HIV-1 infection. Exp Gerontol 2007; 42: 432–437.

41.

Desai

, Landay

Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7: 4–10.

42.

Chaturvedi

A.K.

, Pfeiffer

R.M.

, Chang

, Goedert

J.J.

, Biggar

R.J.

, Engels

E.A.

Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21: 207–213.

43.

Engels

E.A.

, Brock

M.V.

, Chen

, Hooker

C.M.

, Gillison

, Moore

R.D.

Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24: 1383–1388.

44.

Alter

M.J.

Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 Suppl 1: S6–S9.

45.

Chaturvedi

A.K.

, Madeleine

M.M.

, Biggar

R.J.

, Engels

E.A.

Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101: 1120–1130.

46.

Mocroft

, Soriano

, Rockstroh

Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?

AIDS 2005; 19: 2117–2125.

47.

Shibata

, Weiss

L.M.

, Hernandez

A.M.

, Nathwani

B.N.

, Bernstein

, Levine

A.M.

Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood 1993; 81: 2102–2109.

48.

Thio

C.L.

, Seaberg

E.C.

, Skolasky

Jr. . HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921–1926.

49.

Gæde

, Vedel

, Larsen

, Jensen

G.V.

, Parving

H.H.

, Pedersen

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–393.

50.

Mourad

J.J.

, Le

J.S.

Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J Hypertens Suppl 2008; 26: S7–S13.

51.

Justice

A.C.

HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010; 7: 69–76.

52.

Kuller

L.H.

, Tracy

, Belloso

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.

53.

Riddler

S.A.

, Smit

, Cole

S.R.

Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978–2982.

54.

Deeks

S.G.

, Phillips

A.N.

HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338: a3172.

55.

Reekie

, Gatell

, Yust

Fatal and non-fatal AIDS and non-AIDS events in HIV-1 positive individuals with high CD4 counts according to viral load strata. AIDS 2011; 25: 2259–2268.

56.

Deeks

S.G.

, Barbour

J.D.

, Martin

J.N.

, Swanson

M.S.

, Grant

R.M.

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181: 946–953.

57.

Lawrence

, Mayers

D.L.

, Hullsiek

K.H.

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349: 837–846.

58.

Ledergerber

, Lundgren

J.D.

, Walker

A.S.

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51–62.

59.

Deeks

S.G.

, Wrin

, Liegler

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472–480.

60.

Prado

J.G.

, Parkin

N.T.

, Clotet

, Ruiz

, Martinez-Picado

HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure. Clin Infect Dis 2005; 41: 729–737.

61.

Mocroft

, Kirk

, Aldins

Loss to follow-up in an international, multicentre observational study. HIV Med 2008; 9: 261–269.